Hill-Rom Holdings Inc (NYSE:HRC) SVP Andreas G. Frank sold 3,940 shares of Hill-Rom Holdings stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total transaction of $306,689.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,300,005.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hill-Rom Holdings Inc (NYSE:HRC) opened at 75.60 on Friday. Hill-Rom Holdings Inc has a 52-week low of $50.50 and a 52-week high of $84.65. The stock has a market capitalization of $4.98 billion, a PE ratio of 44.06 and a beta of 1.21. The firm’s 50-day moving average is $75.30 and its 200 day moving average is $75.12.

Hill-Rom Holdings (NYSE:HRC) last issued its earnings results on Friday, July 28th. The medical technology company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The firm had revenue of $689.10 million during the quarter, compared to the consensus estimate of $695.50 million. During the same quarter in the prior year, the firm earned $0.81 earnings per share. The business’s quarterly revenue was up 5.1% on a year-over-year basis. On average, equities analysts forecast that Hill-Rom Holdings Inc will post $3.82 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 15th will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Thursday, September 14th. Hill-Rom Holdings’s payout ratio is presently 41.62%.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/17/andreas-g-frank-sells-3940-shares-of-hill-rom-holdings-inc-hrc-stock.html.

A number of large investors have recently modified their holdings of HRC. Independent Portfolio Consultants Inc. increased its stake in Hill-Rom Holdings by 171.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock valued at $107,000 after purchasing an additional 849 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in Hill-Rom Holdings by 3.9% in the first quarter. Meadow Creek Investment Management LLC now owns 1,696 shares of the medical technology company’s stock valued at $120,000 after purchasing an additional 64 shares in the last quarter. Seven Eight Capital LP bought a new stake in Hill-Rom Holdings in the second quarter valued at approximately $127,000. Acrospire Investment Management LLC increased its stake in Hill-Rom Holdings by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after purchasing an additional 600 shares in the last quarter. Finally, Neuburgh Advisers LLC increased its stake in Hill-Rom Holdings by 3.9% in the first quarter. Neuburgh Advisers LLC now owns 2,332 shares of the medical technology company’s stock valued at $165,000 after purchasing an additional 88 shares in the last quarter. 82.31% of the stock is owned by hedge funds and other institutional investors.

HRC has been the topic of several recent research reports. Zacks Investment Research lowered shares of Hill-Rom Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. BidaskClub lowered shares of Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Morgan Stanley lifted their price target on shares of Hill-Rom Holdings from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 30th. Cantor Fitzgerald set a $86.00 price target on shares of Hill-Rom Holdings and gave the stock a “hold” rating in a research report on Friday, July 28th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $84.00 price target on shares of Hill-Rom Holdings in a research report on Sunday, July 30th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Hill-Rom Holdings has an average rating of “Buy” and an average price target of $88.17.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom Holdings (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related stocks with our FREE daily email newsletter.